Stay updated on Lenvatinib and Pembrolizumab in HCC Clinical Trial
Sign up to get notified when there's something new on the Lenvatinib and Pembrolizumab in HCC Clinical Trial page.
Latest updates to the Lenvatinib and Pembrolizumab in HCC Clinical Trial page
- Check4 days agoChange DetectedThe Locations section now lists a large number of trial sites across the United States, Canada, Australia, and many other countries, detailing states, provinces, and cities. This expands the geographic coverage of the LEAP-002 study.SummaryDifference2%
- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check33 days agoChange DetectedPublications description text was slightly revised from 'results of the study' to 'study results', and the page now lists Revision: v3.3.2 (replacing the previous v3.2.0).SummaryDifference0.0%
- Check40 days agoChange DetectedRemoval of the government funding status notice on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%
- Check47 days agoChange DetectedReplaced the location entry 'Tainan City, Taiwan, 70457' with 'Tainan, Taiwan, 70457' to standardize the city name.SummaryDifference0.0%
- Check54 days agoChange DetectedNo additions or deletions were detected in the page content shown in the screenshots. The LEAP-002 study details page remains unchanged in its core information and structure.SummaryDifference0.2%
- Check61 days agoChange DetectedSantiago de Cali entries (760032, 760042) were replaced with Cali entries for Valle del Cauca Department (760032, 760042). The Santiago de Cali locations were removed and the new Cali locations added.SummaryDifference0.0%
Stay in the know with updates to Lenvatinib and Pembrolizumab in HCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lenvatinib and Pembrolizumab in HCC Clinical Trial page.